English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Over the last half century, haematopoietic SCT (HSCT) emerged to become a valid therapeutic option for thousands of patients afflicted with poor-risk malignancies or inherited disorders.1 The Nobel prize for medicine awarded to ED Thomas in 1990 recognized this achievement. Predictions that HSCT would rapidly disappear and be replaced by more modern forms of therapies including targeted therapies and personalized medicine have not been confirmed; in fact, figures are increasing as new transplant centres emerge across the world.

bone marrow transplantation

Regulation of advanced therapy medicinal products will affect the practice of haematopoietic SCT in the near future: a perspective from the EBMT cell-processing committee